Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a blood pressure drug save kidneys in liver patients?

NCT ID NCT06256432

First seen Apr 16, 2026 · Last updated May 22, 2026 · Updated 2 times

Summary

This study tests if ambrisentan, a drug already used for lung blood pressure, can help people with hepatorenal syndrome—a serious kidney problem that can happen in advanced liver disease. About 54 adults will get either ambrisentan or the standard treatment terlipressin while in the hospital, and some may continue ambrisentan at home for up to 60 days. The goal is to see if ambrisentan improves kidney function and reduces deaths.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • All India Institute of Medical Sciences

    New Delhi, National Capital Territory of Delhi, 110029, India

  • Asian Institute of Gastroenterology (AIG)

    Hyderabad, Telangana, 500082, India

  • Aster CMI Hospital

    Bangalore, Karnataka, 560092, India

  • Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College

    Kanpur, Uttar Pradesh, 208002, India

  • Medanta Multi Super Specialty Hospital

    Lucknow, Uttar Pradesh, 226030, India

  • Sir HN Reliance Hospital Foundation

    Mumbai, Maharashtra, 400004, India

Conditions

Explore the condition pages connected to this study.